2020 Report: Recent Advances Across COVID-19 Management, Microbiomics, Genomics, Transcriptomics, and Proteomics Technologies - ResearchAndMarkets.com

The "Recent Advances Across COVID-19 Management, Microbiomics, Genomics, Transcriptomics, and Proteomics Technologies" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent advances in phage therapeutics, skin microbiome, COVID-19 diagnostics and vaccines, and 3D bioprinting. It also evaluates developments across genomic, transcriptomic, and cell-based technological advances for precision medicine applications.

The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery, and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

  • Bacterial Infection Treatment Through Phage-based Therapeutics
  • Bacteriophage and Endolysins for Treatment of AMR
  • Skin Microbes: A Key to Enhance Skin Health and Appearance
  • Microbial Innovations for Skin Health
  • Point-of-Care COVID-19 Diagnostic Test
  • Transforming Rapid Diagnosis for Human Diseases and Agriculture
  • Machine Learning-based Algorithm for Sepsis Diagnosis
  • Digital Predictive Biomarker for Sepsis
  • Competitive DNA Hybridization and Electrochemical Technology for COVID-19 Diagnosis
  • eSensor Technology for Molecular Diagnosis
  • Finnish CE-IVD Diagnostic Test for COVID-19 and Beyond
  • Reliable Diagnosis for Small Laboratories
  • Sepsis Diagnosis Through Cell Mechanical Properties
  • Mechanophenotyping: Next Generation of Diagnosis
  • German mRNA-based Vaccine for COVID-19
  • mRNA Vaccines: A Potential Therapeutics for a Range of Diseases
  • Lipid-enabled mRNA Delivery System
  • Lipid-enabled mRNA Delivery System for COVID-19
  • Cost-effective COVID-19 Testing Kits
  • Academic Collaborations to Develop Diagnostic Kits
  • Technology Attributes
  • Nicotine-related Brain Damage is Repairable
  • Technology Attributes
  • Expanding the Capabilities of Radiotherapy
  • Technology Attributes
  • Increasing Life Expectancy with the Help of Monoclonal Antibodies
  • Gene Therapy for Retinitis Pigmentosa
  • Organoid Model for Preliminary Study
  • Technology Attributes
  • Big Pharma Exploring Exosome Therapeutics
  • Fiber-based Disks to Increase Cell Culture Yield
  • Simple Polymer Material Suitable for Various Cell Lines
  • Antibodies to Treat Metastatic Cancer
  • Ona Therapeutics Carries Out Pre-clinical Trials
  • Liver Cancer Detection by Viral Exposure Signature
  • Growth Opportunities
  • First-in-human Testing of Minimally Invasive Procedure for Treating Hydrocephalus
  • 2.5D Organoid Culture as Model for Bladder Cancer Studies
  • Growing Need for COVID-19 Portable Testing Kits
  • Opportunities Across Industries/ Applications
  • Gene-Edited Immune Cells Grow into Potent Tumor Killers
  • 3D Printing of Compliant Biomedical Sensors Directly on Organs
  • Prospective Neutralizing Antibodies Against COVID-19
  • Next-gen Sequencing Test for COVID-19
  • High-precision Cell Therapy for Blood Cancer
  • Industry Interactions
  • Key Contacts

For more information about this report visit https://www.researchandmarkets.com/r/4y4fyh

Contacts:

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.